<DOC>
	<DOCNO>NCT01219010</DOCNO>
	<brief_summary>The purpose study determine siltuximab effect heart function measure ECG recording specifically determine siltuximab effect QT interval patient Monoclonal Gammopathy Undetermined Significance ( MGUS ) , Smoldering Multiple Myeloma ( SMM ) Indolent Multiple Myeloma ( IMM ) . The study also look see siltuximab may useful treat patient MGUS , SMM IMM .</brief_summary>
	<brief_title>A Study Evaluating Effects Siltuximab Heart Patients With Monoclonal Gammopathy Undetermined Significance , Smoldering Multiple Myeloma , Indolent Multiple Myeloma</brief_title>
	<detailed_description>This research study experimental drug call siltuximab ( also know CNTO 328 ) . Currently study siltuximab , complete ongoing , patient blood cancer multiple myeloma Castleman 's disease solid tumor kidney , ovarian prostate cancer , see siltuximab safe determine effect type cancer . This study do patient Monoclonal Gammopathy Undetermined Significance ( MGUS ) , Smoldering Multiple Myeloma ( SMM ) Indolent Multiple Myeloma ( IMM ) determine siltuximab effect heart function measure ECG recording , specifically determine siltuximab effect QT interval . MGUS , SMM IMM patient usually go develop active multiple myeloma type cancer affect blood bone marrow . The cancer cell bone marrow cause normal bone marrow cell breakdown . This result low level red blood cell ( may make patient feel tire fatigue ) , low level white blood cell ( may increase patient 's chance infection ) low level platelet ( may increase risk bleed ) . The cancer cell cause damage normal bone . This cause bone pain , bone fracture , increase level calcium blood . The cancer cell also make protein ( call M-proteins ) , result damage organ , especially kidney . Siltuximab chimeric ( part mouse part human ) antibody ( immunoglobulin important fight infection ) . It block another small protein call Interleukin 6 ( IL-6 ) . The body make IL-6 naturally , normal level important inflammatory response . But high level IL-6 help cancer cell grow interfere chemotherapy drug kill cancer cell . Cancer-related sickness weight loss , bone weakening , depression link high level IL-6 . This study also look see siltuximab may useful treat patient MGUS , SMM IMM . All participate patient study 6 month receive siltuximab four ( 4 ) time every 3 week dose 15mg per kg bodyweight . Siltuximab give 1 hour intravenous infusion , small tube go directly vein . Following treatment period , patient show response , define 50 % high reduction M-protein blood/urine , may allow continue treatment siltuximab 15mg/kg every 4 week 2 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Paraproteinemias</mesh_term>
	<mesh_term>Monoclonal Gammopathy Undetermined Significance</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Siltuximab</mesh_term>
	<criteria>Diagnosis MGUS ( measurable serum Mprotein &lt; 3 g/dL AND clonal bone marrow plasma cell &lt; 10 % without end organ damage ) , SMM ( measurable serum Mprotein = 3 g/dL OR clonal bone marrow plasma cell = 10 % without end organ damage ) IMM ( measurable serum Mprotein = 3 g/dL OR clonal bone marrow plasma cell = 10 % = 3 lytic bone lesion end organ damage ) Qualifying ECG result check central laboratory Negative urine drug screen substance abuse Qualifying hematology chemistry laboratory result . Diagnosis symptomatic multiple myeloma Prior exposure approve investigational myeloma treatment Prior exposure agent target IL6 IL6 receptor Significant cardiac disease Skin condition likely interfere ECG electrode placement , breast implant , thoracic surgery Received medication know affect QT interval Vaccination live , attenuate vaccine within 4 week Major surgery radiation within 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Monoclonal Gammopathy Undetermined Significance</keyword>
	<keyword>Smoldering Multiple Myeloma</keyword>
	<keyword>Indolent Multiple Myeloma</keyword>
	<keyword>QT</keyword>
	<keyword>Siltuximab</keyword>
	<keyword>CNTO 328</keyword>
	<keyword>IL-6</keyword>
	<keyword>Monoclonal Antibody</keyword>
</DOC>